BioAge Labs (NASDAQ:BIOA) Shares Gap Up – Here’s Why

Shares of BioAge Labs, Inc. (NASDAQ:BIOA) gapped up before the market opened on Tuesday . The stock had previously closed at $18.27, but opened at $19.44. BioAge Labs shares last traded at $18.6450, with a volume of 201,341 shares.

Wall Street Analysts Forecast Growth

BIOA has been the subject of several research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of BioAge Labs in a research report on Thursday, October 30th. Citigroup lifted their price target on BioAge Labs from $10.00 to $15.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Piper Sandler initiated coverage on BioAge Labs in a research report on Tuesday. They set an “overweight” rating for the company. Finally, Wall Street Zen downgraded BioAge Labs from a “hold” rating to a “sell” rating in a report on Monday. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, BioAge Labs presently has an average rating of “Hold” and an average target price of $15.00.

BioAge Labs Price Performance

The firm has a 50-day moving average of $13.62 and a 200 day moving average of $8.33. The stock has a market capitalization of $680.53 million, a price-to-earnings ratio of -12.47 and a beta of 1.38.

BioAge Labs (NASDAQ:BIOA) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.11. The company had revenue of $2.05 million for the quarter.

Insider Buying and Selling at BioAge Labs

In other news, CFO Dov A. Md Goldstein sold 27,000 shares of BioAge Labs stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $19.70, for a total value of $531,900.00. Following the completion of the transaction, the chief financial officer owned 22,408 shares of the company’s stock, valued at $441,437.60. This trade represents a 54.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Paul D. Rubin sold 18,000 shares of the business’s stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $12.00, for a total transaction of $216,000.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 347,004 shares of company stock worth $5,673,859 over the last quarter. 20.82% of the stock is currently owned by insiders.

Institutional Trading of BioAge Labs

Hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. boosted its stake in shares of BioAge Labs by 6.0% during the 3rd quarter. Vanguard Group Inc. now owns 1,651,247 shares of the company’s stock worth $9,709,000 after acquiring an additional 93,694 shares during the period. Geode Capital Management LLC lifted its holdings in BioAge Labs by 60.8% during the 2nd quarter. Geode Capital Management LLC now owns 453,455 shares of the company’s stock valued at $1,873,000 after purchasing an additional 171,426 shares during the last quarter. Millennium Management LLC boosted its position in BioAge Labs by 749.8% during the third quarter. Millennium Management LLC now owns 306,552 shares of the company’s stock worth $1,803,000 after purchasing an additional 270,479 shares during the period. Marshall Wace LLP increased its holdings in shares of BioAge Labs by 324.7% in the second quarter. Marshall Wace LLP now owns 226,789 shares of the company’s stock valued at $937,000 after purchasing an additional 173,388 shares during the last quarter. Finally, Stonepine Capital Management LLC raised its position in shares of BioAge Labs by 202.2% in the second quarter. Stonepine Capital Management LLC now owns 151,085 shares of the company’s stock valued at $624,000 after purchasing an additional 101,085 shares during the period.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.